Computer-aided drug design (CADD) is one of the pivotal approaches to contemporary pre-
clinical drug discovery, and various computational techniques and software programs are …

Polo-like kinase 1 (PLK1) plays an important role in a variety of cellular functions, including
the regulation of mitosis, DNA replication, autophagy, and the epithelial–mesenchymal …

Diffuse midline glioma (DMG) is a uniformly fatal pediatric cancer driven by oncohistones
that do not readily lend themselves to drug development. To identify druggable targets for …

The coiled-coil domain containing protein members have been well documented for their
roles in many diseases including cancers. However, the function of the coiled-coil domain …

Epithelial ovarian cancer (EOC) is one of the deadliest gynaecological malignancies. The
late diagnosis is frequent due to the absence of specific symptomatology and the molecular …

A high incidence of cancer has given rise to the development of more anti-tumor drugs. From
2015 to 2020, fifty-six new small-molecule anticancer drugs, divided into ten categories …

Tropomyosin receptor kinase (TRK) inhibition is an effective therapeutic approach for
treatment of a variety of cancers. Despite the use of first-generation TRK inhibitor (TRKI) …

Tropomyosin receptor kinases (TrkA, TrkB, and TrkC) are attractive therapeutic targets for
multiple cancers. Two first-generation small-molecule Trks inhibitors, larotrectinib and …

Oncogenic fusion proteins, arising from chromosomal rearrangements, have emerged as
prominent drivers of tumorigenesis and crucial therapeutic targets in cancer research. In …

Tropomyosin receptor kinase (TRK) secondary mutations mediating acquired resistance,
especially at the solvent-front (SF) and the DFG motif, represent an unmet clinical need …